Colorectal Cancer | Specialty

Dr. Marshall Discusses Frontline Treatment for CRC

December 22nd 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses frontline treatment options for patients with colorectal cancer (CRC).

Questions Remain on Optimal mCRC Treatment

December 19th 2017

Leonard Saltz, MD, discusses current go-to therapies and overarching questions for mCRC treatment.

Surgery a Mainstay in Colorectal Cancer Treatment

December 19th 2017

William R. Jarnagin, MD, discusses the necessary role of surgery and novel techniques in patients with colorectal cancer.

Dr. Bendell Discusses Pembrolizumab in CRC

December 19th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.

Dr. Kemeny on Liver-Directed Therapy for Metastatic CRC

December 14th 2017

Nancy E. Kemeny, MD, a medical oncologist at Memorial Sloan Kettering Cancer Institute, discusses liver-directed therapies for patients with metastatic colorectal cancer (CRC).

Expert Says Clinical Trials Are Essential for Progress in Metastatic CRC

December 13th 2017

Shubham Pant, MD, stresses the importance of clinical trials as an avenue to establish more novel treatment decisions in colorectal cancer.

Solving the BRAF Mystery in CRC: Genomic Clues Lead to Triplets and Immunotherapy

December 13th 2017

Mutations in the BRAF kinase are found in a relatively small number of patients with metastatic colorectal cancer, but they nonetheless have important implications for prognosis and response to standard therapy.

Dr. Saltz Discusses Chemotherapy in Metastatic CRC

December 12th 2017

Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses chemotherapy for patients with metastatic colorectal cancer.

Experts Describe Challenges of Targeting BRAF Mutations in CRC

December 12th 2017

Tanios Bekaii-Saab, MD, FACP, and Rona D. Yaeger, MD, discuss the current treatment landscape and other key issues relating to this distinct subset of colorectal cancer.

Dr. Pant on the Third-Line Setting for Metastatic CRC

December 6th 2017

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).

Dr. McCollum Discusses Immunotherapy in CRC

December 2nd 2017

A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses integrating immunotherapy into the treatment landscape of colorectal cancer (CRC).

Dr. Bendell on the Treatment of Microsatellite Stable Patients With CRC

November 28th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable.

Role of Immunotherapy Being Defined in Colorectal Cancer

November 23rd 2017

A. David McCollum, MD, discusses the optimal management of CRC in the first-line setting and the ongoing research with checkpoint inhibitors designed to benefit larger groups of patients.

Dr. Pant Discusses the Current Treatment Landscape of CRC

November 22nd 2017

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape of colorectal cancer.

Dr. McCollum on Drug Sequences for Patients With CRC

November 18th 2017

A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses drug sequences for patients with colorectal cancer (CRC).

Dr. McCollum on Treatment in the First-Line Setting for CRC

November 17th 2017

A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

Dr. Bendell on the Future of Regorafenib for Patients With CRC

November 15th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Soft Tissue Sarcoma: An Increasing Number of Options

November 14th 2017

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017

Soft Tissue Sarcoma: Decisions Following Progression

November 14th 2017